Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: A systematic review and meta-analysis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Zhang, Xinji ^a   Li, Yesheng ^a   Li, Hui ^a   Qin, Yingyi ^a   Bai, Chong ^b   Xu, Feng ^a   Zhu, Tianyi ^b   Xu, Jinfang ^a   Wu, Mengjie ^a   Wang, Chaoxiang ^a   Wei, Lixin ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84865092587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040178     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Ferrara N, Davis-Smyth T, (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25.
3. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, et al. (1997) Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3: 861-865.
4. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
5. Pennell NA, Lynch TJ Jr, (2009) Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14: 399-411.
6. Ciardiello F, Tortora G, (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
7. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, et al. (2007) The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75: 770-787.
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
11. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, et al. (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818.
12. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
13. Maione P, Gridelli C, Troiani T, Ciardiello F, (2006) Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 11: 274-284.
14. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, et al. (2006) Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 17 Suppl 7: vii109-114.
15. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, et al. (2009) Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15: 3484-3494.
16. Belani CP, Goss G, Blumenschein G Jr, (2011) Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev doi:10.1016/j.ctrv.2011.1005.1009.
17. Scagliotti GV, (2007) Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer [abstract]. Ann Oncol 18: x32-41.
18. Cascone T, Gridelli C, Ciardiello F, (2007) Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol 19: 98-102.
19. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, et al. (2007) Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6: 471-483.
20. Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 16: 4990-5001.
21. Ciardiello F, Bianco R, Caputo R, Damiano V, Troiani T, et al. (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784-793.
22. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, et al. (2009) Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 27: 2523-2529.
23. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, et al. (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29: 1059-1066.
24. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, et al. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377: 1846-1854.
25. Groen HJM, Socinski M, Grossi F, Juhasz E, Gridelli C, et al. (2010) Randomized phase II study of sunitinib(SU) plus erlotinib (E) VS. placebo (P) plus E for the treatment of metastatic non-small-cell lung cancer [abstract]. Ann Oncol 21: viii122.
26. Govindan R, Krzakowski M, Szczesna A, Strausz J, Makhson A, et al. (2011) Sunitinib in combination with erlotinib for the treatment of advanced/metastatic Non-small Cell Lung Cancer(NSCLC):a phase III study. Available: http://www.astro.org/Meetings/UpcomingMeetings/Thoracic/ScientificProgram/pres/documents/ThorPlenaryGovindan.pdf. Assessed 2011 Jul 10.
27. Spigel DR, Burris HA III, Greco FA, Shipley DL, Friedman EK, et al. (2011) Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 29: 2582-2589.
28. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
29. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
30. Deeks J, Higgins JPT (2011) Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. Available: http://www.cochrane-handbook.org. Accessed 2011 Jul 15.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
32. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
33. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
34. Schiller JH, Akerley WL, Brugger W, Ferrari D, Garmey EG, et al. (2010) Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 28.
35. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH Jr, et al. (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J Clin Oncol 29.
36. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, et al. (2009) A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 4: 1002-1009.
37. Leighl NB, Soria J, Bennouna J, Blais N, Traynor AM, et al. (2010) Phase II study of everolimus plus erlotinib in previouly treated patients with advanced non-small cell lung cancer (NSCLC). [abstract]. J Clin Oncol 28.
38. Miller VA, O'Connor P, Soh CH, Kabbinavar F, (2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 27.
39. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, et al. (2011) The BATTLE trial:personalizing therapy for lung cancer CANCER DISCOVERY 1: doi:10.1158/2159-8274.CD-1110-0010.
40. Johnson BE, Ryan AJ, Heymach J, Stephens C, Kennedy SJ, et al. (2010) Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC [abstract]. J Clin Oncol 28.
41. Stewart LA, Parmar MK, (1993) Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341: 418-422.
42. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH Jr, et al. (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J Clin Oncol 29.
43. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, et al. (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27: 1667-1674.
44. Kim ES, Salgia R, (2009) MET pathway as a therapeutic target. J Thorac Oncol 4: 444-447.